远程医疗公司Hims & Hers Health Inc.(HIMS)今日盘中股价大涨5.2%,引发市场广泛关注。这一强劲涨势主要受到公司将推出新产品以及最新财报表现优异的提振。
消息面上,Hims & Hers Health计划在2025年推出诺和诺德的旧版GLP-1减肥疗法liraglutide非专利版本。此前该公司也已成功以大幅折扣推出诺和诺德流行的减肥疗法Wegovy。这些举措预计将为公司带来新的收入增长动力,从而提振投资者信心。
此外,Hims & Hers Health前三季度财报数据堪称优异。公司实现净利润1亿美元,较去年同期亏损2,479.1万美元扭亏为盈,营收同比大增58.9%至9.954亿美元。出色的业绩体现了该公司在远程医疗领域的强劲竞争力,加之高达80.7%的毛利率,为公司获取更多利润奠定了坚实基础。良好的财报数据和增长前景令分析师普遍给予"买入"评级,进一步刺激了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.